How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Menopause Drugs Market
- By Drug Type: Hormone Replacement Therapy (HRT), Non-Hormonal Therapy, Selective Estrogen Receptor Modulators (SERMs), Antidepressants, Vaginal Estrogens
- By Route of Administration: Oral, Transdermal, Topical, Vaginal, Injectable
- By Therapeutic Application: Vasomotor Symptoms (Hot Flashes), Osteoporosis Prevention, Genitourinary Syndrome of Menopause (GSM), Mood Disorders, Sleep Disturbances
- By End User: Hospitals, Clinics, Specialty Gynecology Centers, Retail Pharmacies, Online Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hormone Replacement Therapy (HRT) leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Menopause Drugs Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Drug Type 5
Route of Administration 5
Therapeutic Application 5
End User 5
Companies profiled
Pfizer Inc.
AbbVie Inc.
Mylan N.V. (Viatris)
Bayer AG
Novo Nordisk A/S
Amgen Inc.
Endo International plc
Theramex
HRA Pharma
Gedeon Richter Plc
Meda AB (subsidiary of Mylan/Viatris)
Mitsubishi Tanabe Pharma Corporation
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Mylan N.V. (Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Novo Nordisk A/S
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Amgen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Endo International plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Theramex
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →HRA Pharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Gedeon Richter Plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Meda AB (subsidiary of Mylan/Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Lundbeck A/S
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Shionogi & Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Ipsen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,523M by 2033 · 7.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hormone Replacement Therapy (HRT)53.7
- Non-Hormonal Therapy15.8
- Selective Estrogen Receptor Modulators (SERMs)14.9
- Antidepressants6.6
- Vaginal Estrogens8.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$660.7M → $1,060M · 6.1%
Europe$460.5M → $890.5M · 8.6%
Asia Pacific$420.4M → $672.9M · 6.1%
Latin America$260.3M → $493.3M · 8.3%
Middle East and Africa$200.2M → $347.5M · 7.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.272026
7.292027
7.302028
7.322029
7.322030
7.342031
7.352032
7.362033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Pfizer Inc.21.4
- AbbVie Inc.16.8
- Mylan N.V. (Viatris)7.2
- Bayer AG9.3
- Novo Nordisk A/S10.0
- Amgen Inc.7.2
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Type36.0%
Route of Administration19.6%
Therapeutic Application21.1%
End User23.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.6
- Europe25.7
- Asia Pacific19.4
- Latin America14.2
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 77 | 73 | 95 | 91 | 84 | 80 | 83 |
| AbbVie Inc. | 84 | 81 | 71 | 88 | 70 | 68 | 77 |
| Mylan N.V. (Viatris) | 87 | 86 | 82 | 75 | 64 | 86 | 80 |
| Bayer AG | 76 | 63 | 59 | 78 | 74 | 70 | 70 |
| Novo Nordisk A/S | 74 | 75 | 71 | 66 | 62 | 59 | 68 |
| Amgen Inc. | 53 | 50 | 68 | 58 | 54 | 51 | 56 |
| Endo International plc | 65 | 61 | 54 | 41 | 63 | 56 | 57 |
| Theramex | 42 | 41 | 58 | 56 | 52 | 48 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Pfizer Inc.
- AbbVie Inc.
- Mylan N.V. (Viatris)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Pfizer Inc. | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| AbbVie Inc. | ✓ | ◐ | − | ✓ | ◐ | − |
| Mylan N.V. (Viatris) | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Bayer AG | ◐ | − | ◐ | ✓ | ✓ | ◐ |
| Novo Nordisk A/S | ✓ | ◐ | ◐ | − | ◐ | − |
| Amgen Inc. | − | − | − | ◐ | − | ◐ |
| Endo International plc | ✓ | ◐ | ◐ | − | − | ◐ |
| Theramex | ◐ | ◐ | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Pfizer Inc.83
2Mylan N.V. (Viatris)80
3AbbVie Inc.77
4Bayer AG70
5Novo Nordisk A/S68
6Endo International plc57
7Amgen Inc.56
8Theramex50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Pfizer Inc.Mylan N.V. (Viatris)
Challenger3
Strong scale, closing on the leaders.
AbbVie Inc.Bayer AGNovo Nordisk A/S
Contender1
Focused players with pockets of strength.
Endo International plc
Niche2
Specialists in a single segment or region.
Amgen Inc.Theramex
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Type in North America, then scale across Menopause Drugs Market — a $117M beachhead inside a $1.69B market.
Beachhead (SOM)$117Mobtainable near-term
Serviceable (SAM)$639Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Hormone Replacement Therapy (HRT)
Best fit — highest urgency & budget in Drug Type.
Economic buyer78 fit
Non-Hormonal Therapy
Strong fit — clear ROI and a fast path to value.
End user69 fit
Selective Estrogen Receptor Modulators (SERMs)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapeutic Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Menopause Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified21%
Evaluation14%
Closed-won7%
$21.7KCAC
$110KLTV
5.1:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Menopause Drugs Market is a high-growth opportunity — $11.0B by 2033, compounding at 11.4%.
TAM · 2025$4.63Btoday
TAM · 2033$11.0Bforecast
CAGR11.4%2027–2033
Cumulative$66.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$11.0BTotal addressable market
SAM$3.96BServiceable available market
SOM$641MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.4% CAGR
Demand compounds through 2033, outpacing GDP across Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$11.0BLarge & growingTAM by 2033 at 11.4% CAGR
$3.96BServiceable nowreachable with today’s model
$641MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.59BBear7.4% CAGR
$11.0BBase11.4% CAGR
$14.1BBull15.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Menopause Drugs Market — a $7.37B market by 2033. Plan: grow share from 8.0% to 17.6%.
Market size · 2033$7.37Btotal addressable
Market CAGR8.9%2027–2033
Target share17.6%from 8.0% today
Revenue ambition$1.30Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 17.6% | At risk |
| Revenue | $553M | $1.30B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 30.8% | 40.1% | Ahead |
| Customer retention | 86.1% | 94.1% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $144M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Menopause Drugs Market conversation — a $1.92B market you can size, segment and defend in minutes.
Market size · 2033$1.92Btotal opportunity
Growth10.5%CAGR to 2033
Addressable buyers1,105+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Type
Goal Grow share in Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 4 mopayback period
$43K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Pfizer Inc.AbbVie Inc.Mylan N.V. (Viatris)Bayer AGNovo Nordisk A/SAmgen Inc.Endo International plcTheramex+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Menopause Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Menopause Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Animal Healthcare Products Market
Animal Healthcare Products Market is valued at USD 40.92 Billion in 2025 and is expected to rea…
$40.9B market · 2025 base year
View reportEthyl (S)-4-Chloro-3-Hydroxybutyrate (CAS 86728-85-0) Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportCollagenase Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportPet Medicine Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportPharmaceutical Lactose Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportCurcuminoid Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportToremifene Citrate (CAS 89778-27-8) Market
Market size, share, segmentation and regional forecast.
$641M market · 2025 base year
View reportGoserelin Acetate (CAS 145781-92-6) Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportIdarubicin (CAS 58957-92-9) Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportAnastrozole (CAS 120511-73-1) Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportLeucogen (CAS 1950-36-3) Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportFludarabine Phosphate (CAS 75607-67-9) Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.